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Chronic infection of the liver by hepatitis C virus (HCV) induces a range of host factors
including IFN-stimulated genes such as ISG15. ISG15 functions as an antiviral factor that limits
virus replication. Previous studies have suggested that ISG15 could influence HCV replication
in both a positive and a negative manner. In this report, we determined the effect of ISG15
on HCV RNA replication in two independent cell lines that support viral genome synthesis
by inhibiting ISG15 expression through small interfering RNA, short-hairpin RNA
and CRISPR/Cas9 gene knockout approaches. Our results demonstrated that ISG15 impairs
HCV RNA replication in both the presence and absence of IFN stimulation, consistent with
an antiviral role for ISG15 during HCV infection. ISG15 conjugation to protein substrates
typically requires the E3 ligase, HERC5. Our results showed that the inhibitory effect of ISG15
on HCV RNA replication does not require its conjugation to substrates by HERC5.
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The outcome of hepatitis C virus (HCV) infection is deter-
mined by an array of host factors that both promote and
limit HCV production. Among the genes upregulated
during infection is IFN-stimulated gene 15 (ISG15)
(MacQuillan et al., 2003; Robinson et al., 2015), a small
ubiquitin-like protein that covalently attaches to lysine resi-
dues on target substrates through post-translational modi-
fication (Loeb & Haas, 1992; Potter et al., 1999). ISG15
conjugation (ISGylation) occurs through a sequential enzy-
mic cascade: (i) activation by the E1 enzyme UBA7; (ii)
conjugation to the E2 enzyme UBE2L6 (UBCH8); and
(iii) ligation to specific protein substrates by ISG15 E3
ligases, most notably HERC5 (Jeon et al., 2010). The post-
translational modification of proteins by ISG15 is reversible
through the catalytic activity of an ISG15-specific protease,
USP18 (Malakhov et al., 2002). Component enzymes of the
ISG15 cascade are transcriptionally upregulated by multiple
pathways involved in sensing immune-related stress, such
as virus infection. Indeed, ISG15 is implicated in the
immune restriction of many clinically important viruses
(Zhao et al., 2013). However, ISG15 can also function in
an unconjugated form as an immunomodulator upon
secretion from cells (Campbell & Lenschow, 2013).
Previously, we identified ISG15 as an antiviral factor in a
small interfering RNA (siRNA) screen in Huh7 and U2OS
cells harbouring stable HCV subgenomic replicons (SGRs)
(Jones et al., 2010). While another report supports an anti-
viral role for ISG15 during RNA replication (Kim & Yoo,
2010), it has also been proposed that ISG15 promotes
HCV infection (Broering et al., 2010; Chen et al., 2010).
Here, we demonstrated that stable ISG15 knockout in
human cells permissive to HCV replication leads to
enhanced levels of viral RNA, in both stable and transient
assays, independently of exogenous IFN stimulation and
HERC5 expression.
To address the potential for both pro- and antiviral roles
for ISG15 in HCV replication, we compared various sys-
tems to deplete or abolish its expression. First, we validated
our previous results (Jones et al., 2010). Transfection of a
pool of ISG15-specific siRNAs (Applied Biosystems) into
Huh7 and U2OS cells that harboured SGR-JFH1-neo,
which encodes the HCV strain JFH-1 replicase proteins
(Targett-Adams & McLauchlan, 2005), suppressed ISG15
mRNA levels by approximately 40 and 50 % in both cell
lines, respectively (Fig. 1a, upper panels). Decreased ISG15
levels correlated with increased steady-state levels of HCV
subgenomic RNA in both cell types (Fig. 1a, lower panels).
The increase was greater in U2OS cells, leading to around
a threefold rise in viral RNA levels, compared with an
,1.5-fold increase in Huh7 cells. We also tested the inhibi-
tory effect of ISG15 following IFN-a-stimulation of SGR cell
lines. In this case, ISG15 mRNA knockdown upon IFN-a
stimulation again resulted in an increase in HCV RNA
levels (Fig. 1b, upper and lower panels). However, the rise
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Fig. 1. Effect of ISG15 knockdown on HCV RNA replication. (a, b) Transient siRNA-mediated suppression of ISG15
increases HCV RNA abundance in the presence and absence of IFN-a. In (a), Huh7 and U2OS cells stably harbouring the
SGR-JFH1-neo SGR were transfected with ISG15-specific and scrambled control siRNAs (siCtrl) and incubated for 48 h.
In (b), the same cell lines were transfected with ISG15-specific and siCtrl siRNAs for 24 h, followed by IFN-a treatment for
48 h. For (a) and (b), levels of ISG15 (upper panels) and HCV RNA (lower panels) were determined by reverse transcription
quantitative PCR (RT-qPCR). (c, d). Constitutive shRNA-mediated knockdown of ISG15 increases viral RNA abundance
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in viral RNA abundance was smaller, although still signifi-
cant, relative to the altered levels in non-IFN-stimulated
cells. These data confirmed our previous findings that
ISG15 inhibits HCV RNA replication independently of
the activation of innate immunity through IFN-mediated
induction.
To explore the effect of ISG15 on HCV RNA synthesis
using the HCV cell culture (HCVcc) infection model,
Huh7 cells constitutively expressing small hairpin RNAs
(shRNAs) against ISG15 were established. Stable Huh7
cell lines (sh1, sh5 and sh6; Fig. 1c) were generated by
transduction with pLKO lentiviruses that expressed control
(shCtrl; 59-TTATCGCGCATATCACGCGTTCAAGAGAAC-
GCGTGATATGCGCGATAATTTTTTACGCGT-39) or anti-
ISG15 shRNAs (sh1, 59-GCGCAGATCACCCAGAAGATT
CAAGAGATCTTCTGGGTGATCTGCGCTTTTTTACGCG
T-39; sh5, 59-GCGGGCTGGAGGGTGTGCATTCAAGAG
ATGCACACCCTCCAGCCCGCTTTTTTACGCGT-39; sh6,
59-GCACCGTGTTCATGAATCTTTCAAGAGAAGATTCA
TGAACACGGTGCTTTTTTACGCGT-39). Lentiviruses ex-
pressing individual shRNAs were generated (Everett et al.,
2006) and used to transduce Huh7 cells, prior to puromy-
cin treatment to select stable cell lines expressing shRNAs.
Cell line sh6 had a constitutive 90 % reduction in basal
ISG15 expression, which correlated with almost complete
loss of ISGylation following IFN-a treatment, similar to
siRNA knockdown (Fig. 1c). Following HCVcc infection
at different m.o.i., sh6 cells maintained lower levels of
ISG15 mRNA at 24 and 48 h post-infection compared
with shCtrl cells (Fig. 1d, upper panel). Reduced abun-
dance of ISG15 mRNA correlated with detection of more
HCV RNA in sh6 as compared with shCtrl cells at different
m.o.i. and at both time points (Fig. 1d, lower panel).
We observed a small increase in viral RNA at 24 h post-
infection in sh6 cells, which was significantly greater at
48 h after infection. This slight lag is presumed to arise
from the time taken for HCV RNA replication to saturate
the pool of input viral genomes detected by reverse tran-
scription quantitative PCR (RT-qPCR) at early time points.
To determine the mechanism through which ISG15
impairs HCV replication, we characterized the expression
of components of the ISGylation system in Huh7 and
U2OS cells. As ISGylation factors are IFN regulated, cells
were treated with IFN-a, -b and -c, and the abundance
of unconjugated and conjugated ISG15 compared with
untreated cells was assessed by Western blot analysis
(Fig. 2a). All IFNs induced unconjugated ISG15 expression,
although to a much lesser degree following IFN-c
treatment. Conjugated and unconjugated ISG15 was
readily observed in Huh7 cells, whereas only unconjugated
ISG15 was evident in U2OS cells and ISGylation products
were barely detected (Fig. 2a, compare left- and right-
hand panels). To examine why ISGylation differed in the
two cell lines, Huh7 and U2OS cells were treated with
IFN-a and the abundance of UBA7 (E1), UBCH8 (E2),
HERC5 (E3) and ISG15 mRNAs was measured (Fig. 2b).
All ISGylation components were upregulated in both cell
lines except for HERC5 mRNA in U2OS cells (Fig. 2b).
This is consistent with and extends previous observations
showing that U2OS cells lack HERC5 mRNA (Mitsui
et al., 1999), the prominent E3 ligase required for efficient
ISGylation. Western blot analysis verified the lack of
HERC5 protein in U2OS cells following IFN-a stimulation
(Fig. 2c). These findings indicated that ISG15-mediated
inhibition of HCV RNA replication in U2OS cells was
independent of HERC5 and its ability to conjugate ISG15
to protein substrates. To further confirm that HERC5 did
not contribute to decreased levels of viral RNA,
Huh7 cells harbouring the SGR-JFH1-neo replicon were
transfected with an HERC5 siRNA. Compared with the
increased levels of HCV RNA seen in replicon-bearing
Huh7 cells transfected with ISG15 siRNA, siRNA-mediated
reduction of HERC5 mRNA did not significantly elevate
the abundance of viral transcripts (data not shown).
As siRNA and shRNA approaches can give non-specific
induction of IFN-regulated genes as well as incomplete
inhibition of target genes, we inactivated ISG15 using the
CRISPR/Cas9-mediated genome editing system (Ran
et al., 2013) to validate an inhibitory role for ISG15 in
HCV replication. U2OS cells were selected for gene editing
as they showed the largest effect on HCV RNA replication
and did not conjugate ISG15 through HERC5. Indels
(editing) were introduced into the ISG15 gene using the
D10A dual ‘nickase’ Cas9 (Cas9n) mutant to limit off-
target effects (Shen et al., 2014). Guide sequences were
chosen computationally (http://crispr.mit.edu/) to disrupt
the ISG15 ORF in exon 2 of the gene (Fig. 3a). Three
pairs of subgenomic RNA (sgRNA) guide sequences were
cloned into the CRISPR/Cas9n expression system plasmid,
PX460, and editing efficiency for each pair in 293T cells
was over 40 %. No ISG15 editing was detected for control
sgRNAs targeting the EGFP ORF or an individual sgRNA
sequence (data not shown). To disrupt the ISG15 gene in
U2OS cells, they were transfected with editing plasmids
containing sgRNAs 1A and 1B (Fig. 3a), transfectants
were enriched after 48 h using puromycin (1 mg ml21)
in HCV-infected cells. In (c), four Huh7-derived cell lines (shCtrl, sh1, sh5 and sh6) were examined for ISG15 depletion fol-
lowing IFN-a (200 IU ml21) treatment for 48 h by both RT-qPCR and Western blot analysis (upper and lower panels,
respectively). Western blot analysis was performed with anti-ISG15 and anti-actin antibodies. In (d), Huh7 shCtrl and sh6
cells were infected at the indicated m.o.i. with strain Jc-1 HCVcc for up to 48 h. For all RT-qPCR experiments in (a)–(d),
levels of ISG15 mRNA and HCV RNA were determined by RT-qPCR and normalized against glyceraldehyde 3-phosphate
dehydrogenase mRNA. Unpaired Student’s t-test statistical comparisons for effects on HCV RNA levels are shown:
*P,0.05; **P,0.005; ***P,0.0005.
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and then diluted to single cells in 96-well plates. Cell clones
containing indels were identified by PCR amplification of
ISG15 from genomic DNA followed by T7 endonuclease
digestion of resulting amplicons (data not shown). Cell
lines, either containing or not containing ISG15 indels,
were then examined by Western blot analysis for ISG15
protein expression using a polyclonal anti-ISG15 antibody
(data not shown). Six clonal lines were chosen for further
analysis: three clones expressing ISG15 and three that
gave no ISG15 expression upon IFN-a stimulation
(Fig. 3b). From a combination of editing, protein
expression and genomic DNA sequence analysis, clone 1
was deemed ISG15+/+, clones 11 and 36 were ISG15+/2
and clones 3, 12 and 18 were ISG152/2 (data not
shown). Heterozygous cells 11 and 36 gave similar ISG15
expression levels compared with U2OS parental cells and
homozygous ISG15+/+ cell line 1 (Fig. 3b). Transient
replication assays were performed in the six selected cell
lines using SGR/JFH1-NEO2AGLUCwt, an SGR based on
SGR-Luc-JFH1 (Targett-Adams & McLauchlan, 2005)
wherein the firefly luciferase gene was replaced by a
fusion protein encoding the neomycin resistance gene
separated from the Gaussia luciferase (GLuc) gene by a
sequence encoding the FMDV 2A peptide sequence. Cells
were transfected by electroporation with in vitro-
transcribed RNA synthesized from SGR/JFH1-
NEO2AGLUCwt and SGR/JFH1-NEO2AGLUCGND, which
expresses inactive HCV NS5B RNA polymerase to block
viral RNA replication. The results showed that GLuc
expression was upregulated more than twofold at 48 and
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Fig. 2. U2OS cells do not express HERC5 and are defective in ISGylation. (a) Comparison of ISGylation in Huh7 and U2OS
cells. Cells were treated with IFN-a, IFN-b and IFN-c (50, 100 and 200 IU ml21) for 48 h or mock treated. Conjugated and
unconjugated ISG15 was examined by Western blot analysis (anti-ISG15 and anti-actin antibodies). (b) Expression of factors
required for ISG15 conjugation. Huh7 and U2OS cells were treated with IFN-a (1000 IU ml21) for 24 h or mock treated.
mRNA levels of UBA7 (E1), UBCH8 (E2), HERC5 (E3) and ISG15 were determined by RT-qPCR. (c) U2OS cells do not
express HERC5 protein. Huh7 and U2OS cells were treated with IFN-a (200 IU ml21) or mock treated for 48 h. Protein
expression was determined by Western blot analysis using anti-ISG15, anti-HERC5 and anti-actin antibodies.
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72 h post-transfection for SGR/JFH1-NEO2AGLUCwt in
cells that lacked ISG15 compared with those containing
the WT gene (Fig. 3c). By contrast, there was no difference
in GLuc expression over time in cells transfected with SGR/
JFH1-NEO2AGLUCGND RNA. These data were consistent
with our results in Fig. 1 and our previously published
study (Jones et al., 2010).
Here, we investigated the role of ISG15 during HCV RNA
replication in two cell lines (Huh7 and U2OS) with a range
of virus systems using multiple loss-of-function approaches
(siRNA, shRNA and CRISPR/Cas9). Uniquely, our study
created stable cell lines in which ISG15 was knocked out
completely. Moreover, we showed that U2OS cells do not
express the HERC5 E3 ligase and therefore are largely
defective for ISG15 conjugation, despite ISG15 showing
antiviral activity against HCV. We do not exclude the
possibility that another E3 ligase conjugates a small pro-
portion of ISG15 to proteins in U2OS cells and that this
population of ISGylated substrates mediates inhibition of
RNA replication.
The data here agree with our previous study that ISG15
exerts an antiviral effect on HCV RNA replication (Jones
et al., 2010). There are conflicting reports on the impact
of ISG15 and ISGylation on HCV RNA replication: another
report supports our findings (Kim & Yoo, 2010), while
other studies have presented contrary evidence that
ISG15/ISGylation is either pro-viral (Broering et al., 2010;
Chen et al., 2010) or does not alter HCV RNA replication
in the absence of IFN (Chua et al., 2009). Given the differ-
ent approaches used by various groups to determine
whether ISG15 affects HCV replication, it is difficult to
reconcile all available data. Moreover, Huh7 cells and
their derivatives are highly heterogeneous and therefore
may influence the observed phenotypes (Bensadoun
et al., 2011; Hoffmann et al., 2014). Consequently, we
selected U2OS cells as an alternative line that supports
HCV RNA replication (Targett-Adams & McLauchlan,
2005) to validate our findings. Inhibiting ISG15 expression
in U2OS cells consistently gives a greater increase in HCV
RNA replication compared with Huh7 cells. This may arise
from a defect in ISGylation in U2OS cells, by virtue of
HERC5’s absence, which could enhance the inhibitory
effect of unconjugated ISG15 on viral RNA synthesis.
Unconjugated ISG15 plays a role in the pathogenesis of
chikungunya virus in a mouse model (Werneke et al.,
Human ISG15: Chr1 (p36.33) 100 bp
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2011) and protects against mycobacterial infections in
humans (Bogunovic et al., 2012). Its mechanism of
action may arise from immunomodulatory functions of
secreted ISG15, but it is also possible that unconjugated
ISG15 interacts with intracellular factors to mediate this
effect. ISG15 is upregulated in HCV-infected liver along
with other ISGs, particularly in individuals with an
IFNL4 TT/CT genotype (rs12979860) (Abe et al., 2011).
Paradoxically, such individuals respond less well to IFN-
based therapy (Ge et al., 2009; Suppiah et al., 2009;
Tanaka et al., 2009). However, the IFNL4 TT/CT genotype
also correlates with lower viral loads (Abe et al., 2011).
Thus, expression of ISGs in the liver, including ISG15, is
likely to suppress virus replication. Our results suggest
that, in concert with other ISGs, ISG15 could lower virus
production in vivo through a mechanism that does not
exclusively require its conjugation to protein substrates.
In light of these findings, further studies are needed to
determine the precise mechanism of action of unconju-
gated ISG15 in virus infection.
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